ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
0 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
91
|
30K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: Significant Uranium Potential Identified at Paddys Well
|
|
stormer
|
16 |
2.4K |
0 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
16
|
2.4K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Vote no to “debt to equity”.
|
|
stormer
|
13 |
2.7K |
1 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
13
|
2.7K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
0 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
91
|
30K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: $12 million Earn-in JV with Delta Lithium (Ti-Tree)
|
|
stormer
|
32 |
6.8K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
32
|
6.8K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Price Target 0.05
|
|
stormer
|
18 |
2.8K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
18
|
2.8K
|
0
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Ponton Uranium Project
|
|
stormer
|
266 |
72K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
266
|
72K
|
3
|
|
ASX - By Stock
|
VSR |
Re:
Ann: $12 million Earn-in JV with Delta Lithium (Ti-Tree)
|
|
stormer
|
32 |
6.8K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
32
|
6.8K
|
0
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Update - Consolidation/Split - OSX
|
|
stormer
|
21 |
5.0K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
21
|
5.0K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: $12 million Earn-in JV with Delta Lithium (Ti-Tree)
|
|
stormer
|
32 |
6.8K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
32
|
6.8K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: $12 million Earn-in JV with Delta Lithium (Ti-Tree)
|
|
stormer
|
32 |
6.8K |
1 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
32
|
6.8K
|
1
|
|
ASX - By Stock
|
VSR |
Re:
Ann: $12 million Earn-in JV with Delta Lithium (Ti-Tree)
|
|
stormer
|
32 |
6.8K |
2 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
32
|
6.8K
|
2
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Ponton Uranium Project
|
|
stormer
|
266 |
72K |
2 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
266
|
72K
|
2
|
|
ASX - By Stock
|
NET |
Re:
Ann: Suspension from Quotation
|
|
stormer
|
10 |
5.2K |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
10
|
5.2K
|
2
|
|
ASX - By Stock
|
5EA |
Re:
5EA set to skyrocket
|
|
stormer
|
1.5K |
740K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
1.5K
|
740K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
91
|
30K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
0 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
35
|
5.6K
|
0
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
91
|
30K
|
4
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
0 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
76
|
17K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
0 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
35
|
5.6K
|
0
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
1 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
35
|
5.6K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
2 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
35
|
5.6K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
5EA |
Re:
5EA set to skyrocket
|
|
stormer
|
1.5K |
740K |
1 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.5K
|
740K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
1 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
35
|
5.6K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
35
|
5.6K
|
0
|
|
ASX - By Stock
|
BPM |
Re:
Ann: Exploration Update Claw Gold Project
|
|
stormer
|
13 |
3.1K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
13
|
3.1K
|
0
|
|
ASX - By Stock
|
W2V |
Re:
Ann: Capital Raising Presentation
|
|
stormer
|
56 |
12K |
3 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
56
|
12K
|
3
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4D - Half Year Report
|
|
stormer
|
5 |
1.2K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
5
|
1.2K
|
0
|
|
ASX - By Stock
|
W2V |
Re:
Ann: Way2VAT completes $4.25M Placement and launches $1M SPP
|
|
stormer
|
30 |
6.2K |
5 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
30
|
6.2K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Are Biotech stocks the next move?
|
|
stormer
|
17 |
4.9K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
17
|
4.9K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
35
|
5.6K
|
0
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
1 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
91
|
30K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
2 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
91
|
30K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4D - Half Year Report
|
|
stormer
|
5 |
1.2K |
3 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
5
|
1.2K
|
3
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
4 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
4
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ detects 19% more breast cancers than leading test
|
|
stormer
|
91 |
30K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
91
|
30K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
stormer
|
35 |
5.6K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
35
|
5.6K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
stormer
|
76 |
17K |
3 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
17K
|
3
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Bio-Gene Receives R&D Tax Incentive
|
|
stormer
|
16 |
3.0K |
0 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
16
|
3.0K
|
0
|
|
ASX - By Stock
|
5EA |
Re:
5EA set to skyrocket
|
|
stormer
|
1.5K |
740K |
5 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
1.5K
|
740K
|
5
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Business Overview and Webinar Presentation
|
|
stormer
|
7 |
1.8K |
1 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
7
|
1.8K
|
1
|
|